Trademarks: Farydak
Molecular Formula: C21H23N3O2
CAS Registry Number: 404950-80-7
CAS Name: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]
acrylamide
Molecular Weight: 349.426
SMILES: CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO
InChI Key: FPOHNWQLNRZRFC-ZHACJKMWSA-N
InChI: InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
Activity: Histone Deacetylase Inhibitor; HDAC Inhibitor; pan-HDAC Inhibitior; Treatment of Multiple Myeloma; Treatment of Pancreatic Cancer Cells
Status: Launched 2015
Originator: Novartis
Panobinostat synthesis: J Med Chem 2011, 54(13), 4694–4720
Panobinostat synthesis: US7989639B2
References:
1. Wang, H.; et. al. Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. J Med Chem 2011, 54(13), 4694–4720. (synthesis in suppl. sheets)
2. Parker, D. J.; et. al. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide. US7989639B2
3. Bair, K. W.; et. al. Hydroxamate derivatives useful as deacetylase inhibitors. WO2002022577A2 (gives an insight to synthetic route, but doesnt provide the desired molecule)
